Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms
- 21 February 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Archiv für Gynäkologie
- Vol. 274 (2), 74-80
- https://doi.org/10.1007/s00404-006-0132-4
Abstract
A clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms. Objective: The objective of the study was to compare the effects of sequential 17β-oestradiol/dydrogesterone and conjugated equine oestrogens (CEE)/norgestrel on lipid parameters, climacteric symptoms, bleeding patterns and tolerability. Study design: This double-blind study was conducted in 193 peri- and post-menopausal women randomised to receive six, 28-day cycles of oral sequential oestradiol 1 mg/dydrogesterone 10 mg or CEE 0.625 mg/norgestrel 0.15 mg. The change from baseline in serum lipids and hot flushes was analysed using a two-way analysis of variance. Results: After 24 weeks there was a statistically significant increase in high-density lipoprotein (HDL) cholesterol in the oestradiol/dydrogesterone group and a significant reduction in the CEE/norgestrel group. The difference between the groups was significant (P=0.001). The number of hot flushes was reduced by 86% in both groups; this improvement was supported by the Greene Climacteric Symptom Scale score, the patients’ opinion and quality of life assessments. The percentage of women experiencing cyclic bleeding was greater with CEE/norgestrel, as was the mean duration and severity of bleeding. Both treatments were well tolerated. Conclusion: Oestradiol/dydrogesterone and CEE/norgestrel were equally effective in treating climacteric symptoms, but oestradiol/dydrogesterone showed some advantages in terms of lipid profile and incidence of bleeding.Keywords
This publication has 24 references indexed in Scilit:
- Should Progestins Be Blamed for the Failure of Hormone Replacement Therapy to Reduce Cardiovascular Events in Randomized Controlled Trials?Arteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Experience of climacteric symptoms among 42–46 and 52–56-year-old womenMaturitas, 2003
- Hormone Replacement Therapy and CardioprotectionAnnals of the New York Academy of Sciences, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Constructing a standard climacteric scaleMaturitas, 1998
- Hormone replacement therapy with dydrogesterone and 17β‐oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow upBJOG: An International Journal of Obstetrics and Gynaecology, 1997
- The risk of acute myocardial infarction after oestrogen and oestrogen‐progestogen replacementBJOG: An International Journal of Obstetrics and Gynaecology, 1992
- Plasma high density lipoproteins. Metabolism and relationship to atherogenesis.JCI Insight, 1990